Medicines used in respiratory diseases only seen in children

W. Lenney; A. L. Boner; L. Bont; A. Bush; K-H. Carlsen; E. Eber; B. Fauroux; M. Goetz; A. Greenough; J. Grigg; J. Hull; J. Kimpen; M. Sanchez Luna; F. M. de Benedictis

doi:10.1183/09031936.00166508

Medicines used in respiratory diseases only seen in children

W. Lenney, A. L. Boner, L. Bont, A. Bush, K-H. Carlsen, E. Eber, B. Fauroux, M. Goetz, A. Greenough, J. Grigg, J. Hull, J. Kimpen, M. Sanchez Luna, F. M. de Benedictis

Research output: Contribution to journal › Literature review › peer-review

38 Citations (Scopus)

Abstract

Detailed literature searches were carried out in seven respiratory disease areas. Therapeutic evidence for efficacy of medicinal products was assessed using the Grades of Recommendation, Assessment and Evaluation (GRADE) methodology, as well as an assessment of safety and side-effects. Systemic corticosteroids may reduce the development of bronchopulmonary dysplasia but have serious side-effects. Antioxidants need further study to demonstrate whether they have long-term benefits. Treatments for acute bronchiolitis have shown little benefit but new antiviral and monoclonal antibodies need further assessment. Well-constructed studies are needed to confirm the value of inhaled corticosteroids and/or montelukast in the management of viral-induced wheeze. Corticosteroids are the treatment of choice in croup. Minimal or no information is available for the treatment of congenital lung abnormalities, bronchiolitis obliterans and interstitial lung disease.

Original language	English
Pages (from-to)	531 - 551
Number of pages	21
Journal	European Respiratory Journal
Volume	34
Issue number	3
DOIs	https://doi.org/10.1183/09031936.00166508
Publication status	Published - Sept 2009

Access to Document

10.1183/09031936.00166508

Cite this

@article{e9039bb25e874af68000e032988f1158,

title = "Medicines used in respiratory diseases only seen in children",

abstract = "Detailed literature searches were carried out in seven respiratory disease areas. Therapeutic evidence for efficacy of medicinal products was assessed using the Grades of Recommendation, Assessment and Evaluation (GRADE) methodology, as well as an assessment of safety and side-effects. Systemic corticosteroids may reduce the development of bronchopulmonary dysplasia but have serious side-effects. Antioxidants need further study to demonstrate whether they have long-term benefits. Treatments for acute bronchiolitis have shown little benefit but new antiviral and monoclonal antibodies need further assessment. Well-constructed studies are needed to confirm the value of inhaled corticosteroids and/or montelukast in the management of viral-induced wheeze. Corticosteroids are the treatment of choice in croup. Minimal or no information is available for the treatment of congenital lung abnormalities, bronchiolitis obliterans and interstitial lung disease.",

author = "W. Lenney and Boner, {A. L.} and L. Bont and A. Bush and K-H. Carlsen and E. Eber and B. Fauroux and M. Goetz and A. Greenough and J. Grigg and J. Hull and J. Kimpen and {Sanchez Luna}, M. and {de Benedictis}, {F. M.}",

year = "2009",

month = sep,

doi = "10.1183/09031936.00166508",

language = "English",

volume = "34",

pages = "531 -- 551",

journal = "European Respiratory Journal",

issn = "1399-3003",

publisher = "European Respiratory Society",

number = "3",

}

TY - JOUR

T1 - Medicines used in respiratory diseases only seen in children

AU - Lenney, W.

AU - Boner, A. L.

AU - Bont, L.

AU - Bush, A.

AU - Carlsen, K-H.

AU - Eber, E.

AU - Fauroux, B.

AU - Goetz, M.

AU - Greenough, A.

AU - Grigg, J.

AU - Hull, J.

AU - Kimpen, J.

AU - Sanchez Luna, M.

AU - de Benedictis, F. M.

PY - 2009/9

Y1 - 2009/9

N2 - Detailed literature searches were carried out in seven respiratory disease areas. Therapeutic evidence for efficacy of medicinal products was assessed using the Grades of Recommendation, Assessment and Evaluation (GRADE) methodology, as well as an assessment of safety and side-effects. Systemic corticosteroids may reduce the development of bronchopulmonary dysplasia but have serious side-effects. Antioxidants need further study to demonstrate whether they have long-term benefits. Treatments for acute bronchiolitis have shown little benefit but new antiviral and monoclonal antibodies need further assessment. Well-constructed studies are needed to confirm the value of inhaled corticosteroids and/or montelukast in the management of viral-induced wheeze. Corticosteroids are the treatment of choice in croup. Minimal or no information is available for the treatment of congenital lung abnormalities, bronchiolitis obliterans and interstitial lung disease.

AB - Detailed literature searches were carried out in seven respiratory disease areas. Therapeutic evidence for efficacy of medicinal products was assessed using the Grades of Recommendation, Assessment and Evaluation (GRADE) methodology, as well as an assessment of safety and side-effects. Systemic corticosteroids may reduce the development of bronchopulmonary dysplasia but have serious side-effects. Antioxidants need further study to demonstrate whether they have long-term benefits. Treatments for acute bronchiolitis have shown little benefit but new antiviral and monoclonal antibodies need further assessment. Well-constructed studies are needed to confirm the value of inhaled corticosteroids and/or montelukast in the management of viral-induced wheeze. Corticosteroids are the treatment of choice in croup. Minimal or no information is available for the treatment of congenital lung abnormalities, bronchiolitis obliterans and interstitial lung disease.

U2 - 10.1183/09031936.00166508

DO - 10.1183/09031936.00166508

M3 - Literature review

SN - 1399-3003

VL - 34

SP - 531

EP - 551

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

ER -

Medicines used in respiratory diseases only seen in children

Abstract

Access to Document

Fingerprint

Cite this